Influence of Viscum album L (European Mistletoe) Extracts on Quality of Life in Cancer Patients: A Systematic Review of Controlled Clinical Studies

Integrative Cancer Therapies

Volumn 9, Issue 2, 2010, Pages 142-157

  Kienle, Gunver S ^a   Kiene, Helmut ^a  

^a Institut fur angewandte Erkenntnistheorie und medizinische Methodologie e V   (Germany)

Author keywords

clinical trials; complementary therapies; herbal medicine; mistletoe; neoplasms; quality of life; Viscum album

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; DOXYCYCLINE; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; LENTINAN; METHOTREXATE; VISCUM ALBUM EXTRACT; PLANT EXTRACT;

ADJUVANT CHEMOTHERAPY; ANXIETY; APPETITE; BACKACHE; BREAST CANCER; BURNING SENSATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; CONSTIPATION; COPING BEHAVIOR; DATA BASE; DEPRESSION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ENERGY; EXHAUSTION; FATIGUE; FEVER; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HEADACHE; HUMAN; IRRITABILITY; LUNG CANCER; MELANOMA; MUCOSA INFLAMMATION; NAUSEA; NEOPLASM; OVARY CANCER; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; RISK REDUCTION; SIDE EFFECT; SLEEP; STOMATITIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UTERINE CERVIX CANCER; UTERUS CANCER; VOMITING; WELLBEING; WORK CAPACITY; ANIMAL; CHEMISTRY; CONTROLLED CLINICAL TRIAL; MULTIMODALITY CANCER THERAPY; VISCUM ALBUM;

ANIMALS; COMBINED MODALITY THERAPY; CONTROLLED CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; PLANT EXTRACTS; QUALITY OF LIFE; QUESTIONNAIRES; VISCUM ALBUM;

EID: 77954199043     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735410369673     Document Type: Review

References (96)

1. Molassiotis A., Fernandez-Ortega P., Pud D., et al. Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol. 2005; 16: 655-663. (Pubitemid 40613334)
2. Fasching PA, Thiel F., Nicolaisen-Murmann K., et al. Association of complementary methods with quality of life and life satisfaction in patients with gynecologic and breast malignancies. Support Care Cancer. 2007; 55: 1277-1284.
3. Molassiotis A., Scott JA, Kearney N., et al. Complementary and alternative medicine use in breast cancer patients in Europe. Support Care Cancer. 2006; 14: 260-267. (Pubitemid 43247930)
4. Schwabe U, Paffrath D, eds. Arzneiverordnungsreport 2005. Heidelberg, Germany: Springer Verlag; 2005.
5. Petru E., Schmied P., Petru C. Komplementäre Maßnahmen bei Patientinnen mit gynäkologischen Malignomen unter Chemound Hormontherapie: Bestandsaufnahme und kritische Überlegungen für die Praxis. Geburtshilfe Frauenheilkd. 2001; 61: 75-78.
6. Mansky PJ, Grem J., Wallerstedt DB, Monahan BP, Blackman MR Mistletoe and Gemcitabine in patients with advanced cancer: a model for the phase I study of botanicals and botanical-drug interactions in cancer therapy. Integr Cancer Ther. 2003; 2: 345-352.
7. Endo Y., Tsurugi K., Franz H. The site of action of the A-chain of mistletoe lectin I on eukaryotic ribosomes. FEBS Lett. 1988; 231: 378-380.
8. Stirpe F., Sandvig K., Olsnes S., Pihl A. Action of viscumin, a toxic lectin from mistletoe, on cells in culture. J Biol Chem. 1982; 257: 13271-13277.
9. Stirpe F., Barbieri L., Battelli MG, Soria M., Lappi DA Ribosome-inactivating proteins from plants: present status and future prospects. Biotechnology (N Y). 1992; 10: 405-412.
10. Peumans WJ, Verhaert P., Pfüller U., Van Damme EJM. Isolation and partial characterization of a small chitin-binding lectin from mistletoe (Viscum album). FEBS Lett. 1996; 396: 261-265.
11. Klett CY, Anderer FA Activation of natural killer cell cytotoxicity of human blood monocytes by a low molecular weight component from Viscum album extract. Arzneimittelforschung. 1989; 39: 1580-1585.
12. Mueller EA, Anderer FA A Viscum album oligosaccharide activating human natural cytotoxicity is an interferon gamma inducer. Cancer Immunol Immunother. 1990; 32: 221-227.
13. Orhan DD, Küpeli E., Yesilada E., Ergun F. Anti-inflammatory and antinociceptive activity of flavonoids isolated from Viscum album ssp. album. Z Naturforsch C. 2006; 61: 26-30.
14. Winkler K., Leneweit G., Schubert R. Characterization of membrane vesicles in plant extracts. Colloids Surf B Biointerfaces. 2005; 45: 57-65.
15. Jager S., Winkler K., Pfuller U., Scheffler A. Solubility studies of oleanolic acid and betulinic acid in aqueous solutions and plant extracts of Viscum album L. Planta Med. 2007; 73: 157-162.
16. Kienle GS, Kiene H. Die Mistel in der Onkologie: Fakten und konzeptionelle Grundlagen. Stuttgart, Germany: Schattauer Verlag; 2003.
17. Büssing A, ed. Mistletoe. The Genus Viscum. Amsterdam, the Netherlands: Hardwood Academic; 2000.
18. Eggenschwiler J., von BL, Stritt B., et al. Mistletoe lectin is not the only cytotoxic component in fermented preparations of Viscum album from white fir (Abies pectinata). BMC Complement Altern Med. 2007; 7: 14.
19. Büssing A., Schietzel M. Apoptosis-inducing properties of Viscum album L. extracts from different host trees, correlate with their content of toxic mistletoe lectins. Anticancer Res. 1999; 19: 23-28.
20. Elsässer-Beile U., Lusebrink S., Grussenmeyer U., Wetterauer U., Schultze-Seemann W. Comparison of the effects of various clinically applied mistletoe preparations on peripheral blood leukocytes. Arzneimittelforschung. 1998; 48: 1185-1189.
21. Valentiner U., Pfüller U., Baum C., Schumacher U. The cytotoxic effect of mistletoe lectins I, II and III on sensitive and multidrug resistant human colon cancer cell lines in vitro. Toxicology. 2002; 171: 187-199.
22. Siegle I., Fritz P., McClellan M., Gutzeit S., Murdter TE Combined cytotoxic action of Viscum album agglutinin-1 and anticancer agents against human A549 lung cancer cells. Anticancer Res. 2001; 21: 2687-2691.
23. Bantel H., Engels IH, Voelter W., Schulze-Osthoff K., Wesselborg S. Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis. Cancer Res. 1999; 59: 2083-2090.
24. Mueller EA, Anderer FA Synergistic action of a plant rhamnogalacturonan enhancing antitumor cytotoxicity of human natural killer and lymphokine-activated killer cells: chemical specificity of target cell recognition. Cancer Res. 1990; 50: 3646-3651.
25. Zhu HG, Zollner TM, Klein-Franke A., Anderer FA Enhancement of MHC-unrestricted cytotoxic activity of human CD56+CD3-natural killer (NK) cells and CD+T cells by rhamnogalacturonan: target cell specificity and activity against NK-insensitive targets. J Cancer Res Clin Oncol. 1994;(120). 383-388.
26. Park W.-B, Lyu SY, Kim JH, et al. Inhibition of tumor growth and metastasis by Korean mistletoe lectin is associated with apoptosis and antiangiogenesis. Cancer Biother Radiopharm. 2001; 16: 439-447.
27. Van Huyen JP, Bayry J., Delignat S., et al. Induction of apoptosis of endothelial cells by Viscum album: a role for anti-tumoral properties of mistletoe lectins. Mol Med. 2002; 8: 600-606.
28. Kienle GS, Kiene H., Albonico HU Anthroposophic Medicine: Effectiveness, Utility, Costs, Safety. Stuttgart, Germany: Schattauer Verlag; 2006.
29. Kienle GS, Kiene H. Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts. Eur J Med Res. 2007; 12: 103-119.
30. Stauder H., Kreuser E-D. Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research. Onkologie. 2002; 25: 374-380.
31. Kienle GS, Glockmann A., Schink M., Kiene H. Viscum album L. extracts in breast and gynaecologic cancers: a systematic review of clinical and preclinical research. J Exp Clin Cancer Res. 2009; 28: 79. http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC2711058/. Accessed April 5, 2010.
32. National Cancer Institute. Mistletoe extracts (PDQ′). http://www.cancer.gov/cancertopics/pdq/cam/mistletoe/healthprofessional/ allpages. Accessed April 5, 2010.
33. Kienle GS, Berrino F., Büssing A., Portalupi E., Rosenzweig S., Kiene H. Mistletoe in cancer: a systematic review on controlled clinical trials. Eur J Med Res. 2003; 8: 109-119.
34. Ernst E., Schmidt K., Steuer-Vogt MK Mistletoe for cancer? A systematic review of randomized clincial trials. Int J Cancer. 2003; 107: 262-267.
35. Horneber MA, Bueschel G., Huber R., Linde K., Rostock M. Mistletoe therapy in oncology. Cochrane Database Syst Rev. 2008;(2). CD003297.
36. Lange-Lindberg AM, Velasco Garrido M., Busse R. Misteltherapie als begleitende Behandlung zur Reduktion der Toxizität der Chemotherapie maligner Erkrankungen. GMS Health Technol Assess 2006. http://portal.dimdi.de/ de/hta/hta-berichte/hta117-bericht-de.pdf. Accessed April 5, 2010.
37. Melzer J., Iten F., Hostanska K., Saller R. Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases. Forsch Komplementmed. 2009; 16: 217-226.
38. Karnofsky DA, Burchenal JH The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, ed. Evaluation of Chemotherapeutic Agents. New York, NY: Columbia University Press; 1949: 191-205.
39. Garratt A., Schmidt L., Mackintosh A., Fitzpatrick R. Quality of life measurement: bibliographic study of patient assessed health outcome measures. Br Med J. 2002; 324: 1417.
40. Fayers PM, Machin D. Quality of Life. The Assessment, Analysis and Interpretation of Patient-Reported Outcomes. 2 nd ed. Chichester, UK: Wiley; 2007.
41. Khan KS, ter Riet G., Glanville J., Sowden AJ, Kleijnen J. Undertaking Systematic Reviews of Research on Effectiveness. CRD'S Guidance for those Carrying Out or Commissioning Reviews. CRD Report Number 4 (2 nd ed.). York, UK: NHS Centre for Reviews and Dissemination; 2001.
42. Kleijnen J., Knipschild P. Mistletoe treatment for cancer: review of controlled trials in humans. Phytomedicine. 1994; 1: 255-260.
43. Efficace F., Bottomley A., Osoba D., et al. Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials-does HRQOL evaluation in prostate cancer research inform clinical decision making ? J Clin Oncol. 2003; 21: 3502-3511.
44. Semiglasov VF, Stepula VV, Dudov A., Lehmacher W., Mengs U. The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res. 2004; 24: 1293-1302.
45. Semiglasov VF, Stepula VV, Dudov A., Schnitker J., Mengs U. Quality of life is improved in breast cancer patients by standardised mistletoe extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res. 2006; 26: 1519-1530.
46. Borrelli E. Evaluation of the quality of life in breast cancer patients undergoing lectin standardized mistletoe therapy. Minerva Med. 2001; 92 (suppl 1). 105-107.
47. Auerbach L., Dostal V., Václavik-Fleck I., et al. Signifikant hüherer Anteil aktivierter NK-Zellen durch additive Misteltherapie bei chemotherapierten Mamma-Ca-Patientinnen in einer prospektiven randomisierten doppelblinden Studie. In: Scheer R, Bauer R, Becker H, Fintelmann V, Kemper FH, Schilcher H, eds. Fortschritte in der Misteltherapie. Aktueller Stand der Forschung und klinischen Anwendung. Essen, Germany: KVC Verlag; 2005: 543-554.
48. Heiny B.-M. Additive Therapie mit standardisiertem Mistelextrakt reduziert die Leukopenie und verbessert die Lebensqualität von Patientinnen mit fortgeschrittenem Mammakarzinom unter palliativer Chemotherapie (VEC-Schema). Krebsmedizin. 1991; 12: 1-14.
49. Dold U., Edler L., Mäurer HCh, et al. Krebszusatztherapie beim fortgeschrittenen nicht-kleinzelligen Bronchialkarzinom. Stuttgart, Germany: Georg Thieme Verlag; 1991.
50. Piao BK, Wang YX, Xie GR, et al. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res. 2004; 24: 303-309.
51. Kim M-H., Park Y-K., Lee S-H., et al. Comparative study on the effects of a Viscum album (L.) extract (mistletoe) and doxycycline for pleurodesis in patients with malignant pleural effusion. 51th Meeting of The Korean Association of Internal Medicine. Translation by Helixor Heilmittel GmbH. Korean J Med. 1999; 57 (suppl II). S121.
52. Longhi A., Mariani E., Kuehn JJ A randomized study with adjuvant mistletoe versus oral Etoposide on post relapse disease-free survival in osteosarcoma patients. Eur J Integr Med. 2009; 1: 27-33.
53. Grossarth-Maticek R., Ziegler R. Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador′). Forsch Komplementmed. 2007; 14: 140-147. (Pubitemid 47013381)
54. Grossarth-Maticek R., Ziegler R. Prospective controlled cohort studies on long-term therapy of ovarian cancer patients with mistletoe (Viscum album L.) extracts Iscador. Arzneimittelforschung. 2007; 57: 665-678. (Pubitemid 350075413)
55. Grossarth-Maticek R., Ziegler R. Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador). Forsch Komplementmed. 2006; 13: 285-292.
56. Loewe-Mesch A., Kuehn JH, Borho K., et al. Adjuvante simultane Mistel-/Chemotherapie bei Mammakarzinom: Einfluss auf Immunparameter, Lebensqualität und Verträglichkeit. Forsch Komplementmed. 2008; 15: 22-30.
57. Bock PR, Friedel WE, Hanisch J., Karasmann M., Schneider B. Wirksamkeit und Sicherheit der komplementären Langzeitbehandlung mit einem standardisierten Extrakt aus Europäischer Mistel (Viscum album L.) zusätzlich zur konventionellen adjuvanten onkologischen Therapie bei primärem, nicht metastasiertem Mammakarzinom. Ergebnisse einer multizentrischen, komparativen, epidemiologischen Kohortenstudie in Deutschland und der Schweiz. Arzneimittelforschung. 2004; 54: 456-466.
58. Friedel WE, Matthes H., Bock PR Mistletoe in supportive care in patients with primary non-metastatic colorectal carcinoma. Paper presented at the ASMO Conference Lugano; 5-8 July, 2007; Lugano, Switzerland.
59. Matthes H., Friedel WE, Bock PR Supportive care in pancreatic carcinoma patients treated with a fermented mistletoe (Viscum album L.) extract. Paper presented at the ASMO Conference Lugano; 5-8 July, 2007; Lugano, Switzerland.
60. Beuth J., Schneider B., Schierholz JM Impact of complementary treatment of breast cancer patients with standardized mistletoe extract during aftercare: a controlled multicenter comparative epidemiological cohort study. Anticancer Res. 2008; 28: 523-528.
61. Friedel WE, Matthes H., Bock PR, Zänker KS Systematic evaluation of the clinical effects of supportive mistletoe treatment within chemo-and/or radiotherapy protocols and long-term mistletoe application in nonmetastatic colorectal carcinoma: multicenter, controlled, observational cohort study. J Soc Integr Oncol. 2009; 7: 137-145.
62. Schumacher K., Schneider B., Reich G., et al. Influence of postoperative complementary treatment with lectin-standardized mistletoe extract on breast cancer patients: a controlled epidemiological multicentric retrolective cohort study. Anticancer Res. 2003; 23: 5081-5088.
63. Kleeberg UR, Suciu S., Brücker EB, et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: rIFNα2b versus rIFN-γ versus Iscador M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3mm) or regional lymph node metastasis. Eur J Cancer. 2004; 40: 390-402.
64. Cazacu M., Oniu T., Lungoci C., et al. The influence of Isorel on the advanced colorectal cancer. Cancer Biother Radiopharm. 2003; 18: 27-34.
65. Eisenbraun J. Verbesserung der Lebensqualität durch eine Misteltherapie (abnobaVISCUM©) bei Patienten mit Magenkarzinom: Ergebnisse einer randomisierten, kontrollierten Studie. Zeitschrift für Phytotherapie 30 (S01):DOI: 10.1055/ s-0029-1239850, 2009.
66. Trüger W., Matijaševic M., Ždrale Z., Tisma N., Jezdic S. Additional therapy with mistletoe extracts in breast cancer patients receiving chemotherapy: a prospective randomized open label pilot study. In: Scheer R, Alban S, Becker H, et al, eds. Die Mistel in der Tumortherapie 2. Aktueller Stand der Forschung und klinische Anwendung. Essen, Germany: KVC-Verlag; 2009. p. 509-521.
67. Büssing A., Brückner U., Enser-Weis U., et al. Modulation of chemotherapy-associated immunosuppression by intravenous application of Viscum album L. extract (Iscador): a randomised physe II study. Eur J Integr Med. 2008; 1 (suppl 1). S44-S54.
68. Heiny B-M., Albrecht V., Beuth J. Lebensqualitätsstabilisierung durch Mistellektin-1 normierten Extrakt beim fortgeschrittenen kolorektalen Karzinom. Onkologe. 1998; 4 (suppl 1). 35-39.
69. Heiny B.-M. Albrecht V. Komplementäre Therapie mit Mistellektin-1-normiertem Extrakt. Lebensqualitätsstabilisierung beim fortgeschrittenen kolorektalen Karzinom: Fakt oder Fiktion ? Med Welt. 1997; 48: 419-423.
70. Steuer-Vogt MK, Bonkowsky V., Ambrosch P., et al. The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur J Cancer. 2001; 37: 23-31.
71. Steuer-Vogt MK, Bonkowsky V., Scholz M., Fauser C., Licht K., Ambrosch P. Einfluss eines ML-1-normierten Mistelextraktes auf die Lebensqualität bei Patienten mit Kopf-Hals-Karzinomen. HNO. 2006; 54: 277-286.
72. Lenartz D., Stoffel B., Menzel J., Beuth J. Immunoprotective activity of the galactoside-specific lectin from mistletoe after tumor destructive therapy in glioma patients. Anticancer Res. 1996; 16: 3799-3802.
73. Enesel MB, Acalovschi I., Grosu V., et al. Perioperative application of the Viscum album extract Isorel in digestive tract cancer patients. Anticancer Res. 2005; 25: 4583-4590.
74. Grossarth-Maticek R., Ziegler R. Randomized and nonrandomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador). Eur J Med Res. 2008; 13: 107-120.
75. Grossarth-Maticek R., Ziegler R. Wirksamkeit und Unbedenklichkeit einer Langzeitbehandlung von Melanompatienten mit einem Mistelpräparat (Iscador′). Schweiz Z Ganzheitsmed. 2007; 19: 325-332.
76. Eggermont A., Kleeberg UR, Ruiter DJ, Suciu S. European Organization for Research and Treatment of Cancer Melanoma Group trial experience with more than 2,000 patients, evaluating adjuvant treatment with low or intermediate doses of interferon alpha-2b. In: American Society of Clinical Oncology, ed. American Society of Clinical Oncology Educational Book. Baltimore, MD: Lippincott Williams & Wilkins; 2001: 88-93.
77. Grossarth-Maticek R., Kiene H., Baumgartner S., Ziegler R. Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Altern Ther Health Med. 2001; 7: 57-78.
78. Trüger W., Jezdic S., Zdrale Z., Tisma N., Hamre HJ, Matijasevic M. Quality of life and neutropenia in patients with early stage breast cancer: a randomized pilot study comparing additional treatment with mistletoe extract to chemotherapy alone. Breast Cancer. 2009; 3: 35-45.
79. Mansky PJ, Wallerstedt DB, Monahan BP, et al. Phase I study of mistletoe extract/gemcitabine combination treatment in patients with advanced solid tumors. Onkologie. 2008; 31 (suppl 1). 200.
80. Kirchberger I., Wetzel D., Finger T. Development and validation of an instrument to measure the effects of a mistletoe preparation on quality of life of cancer patients: the Life Quality Lectin-53 (LQL-53) Questionnaire. Qual Life Res. 2004; 13: 463-479.
81. Joly F., Vardy J., Pintilie M., Tannock IF Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer. Ann Oncol. 2007; 18: 1935-1942.
82. Büssing A., Girke M., Heckmann C., Schad F., Ostermann T., Krüz M. Validation of the self-regulation questionnaire as a measure of health in quality of life research. Eur J Med Res. 2009; 14: 223-227.
83. Rostock M., Huber R. Randomized and double-blind studies: demands and reality as demonstrated by two examples of mistletoe research. Forsch Komplementmed. 2004; 11 (suppl 1). 18-22.
84. Chvetzoff G., Tannock I. Placebo effects in oncology. J Natl Cancer Inst. 2003; 95: 19-29.
85. Hróbjartsson A., Gøtzsche P. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med. 2001; 344: 1594-1602.
86. Kienle GS, Kiene H. The powerful placebo effect: fact or fiction ? J Clin Epidemiol. 1997; 50: 1311-1318.
87. Koes BW, Bouter LM, van Mameren H., et al. Randomised clinical trial of manipulative therapy and physiotherapy for resistant back and neck complaints: results of one year follow up. Br Med J. 1992; 304: 601-605.
88. Heiny B.-M, Beuth J. Mistletoe extract standardized for galactoside-spcific lectin (ML-1) induces β-endorphin release and immunopotentiation in breast cancer patients. Anticancer Res. 1994; 14: 1339-1342.
89. Büssing A., Trüger W., Stumpf C., Schietzel M. Local reactions to treatments with Viscum album L. extracts and their association with T-lymphocyte subsets and quality of life. Anticancer Res. 2008; 28: 1893-1898.
90. Curt G., Johnston PG Cancer fatigue: the way forward. Oncologist. 2003; 8 (suppl 1). 27-30.
91. Stone P., Richardson A., Ream E., Smith AG, Kerr DJ, Kearney N. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol. 2000; 11: 971-975.
92. Hofman M., Ryan JL, Figueroa-Moseley CD, Jean-Pierre P., Morrow GR Cancer-related fatigue: the scale of the problem. Oncologist. 2007; 12 (suppl 1). 4-10.
93. Ahlberg K., Ekmann T., Gaston-Johansson F., Mock V. Assessment and management of cancer-related fatigue in adults. Lancet. 2003; 362: 640-650.
94. Carroll JK, Kohli S., Mustian KM, Roscoe JA, Morrow GR Pharmacologic treatment of cancer-related fatigue. Oncologist. 2007; 12 (suppl 1). 43-51.
95. Mustian KM, Morrow GR, Carroll JK, Figueroa-Moseley CD, Jean-Pierre P., Williams GC Integrative nonpharmacologic behavioral interventions for the management of cancer-related fatigue. Oncologist. 2007; 12 (suppl 1). 51-67.
96. Wode K., Schneider T., Lundberg I., Kienle GS Mistletoe treatment in cancer-related fatigue: a case report. Cases J. 2009; 2: 77.